Magnetic Molecular Energizing (MME) treatment is currently under active research, so the full extent and limitations of this treatment method are not known at this time. In general terms, it is safe, painless, accelerates healing, is noninvasive, does not have the allergic or interaction complications of multi-prescription drugs and does not carry the risks of more aggressive treatment methods such as experimental drugs or surgery.

MME offers hope for many diseases previously considered untreatable by conventional methods. It has thus far been successful with a wide variety of ailments, such as spinal cord injury, brain injury, stroke impairment, multiple sclerosis, Becker’s muscular dystrophy, cerebral palsy, Parkinson’s disease, Alzheimer’s disease, congestive heart failure, and orthopedic conditions involving bone and joint repair.

MME research is being conducted under the auspices of an Institutional Review Board (IRB) as outlined in the FDA regulations. The IRB consists of five or more physicians or health professionals that review the records of all treatment cases.

Since extensive toxicity studies have already been conducted, MME research can focus on responses or benefits to an array of diagnosed conditions. When significant numbers of cases in any given category of treatment have been accumulated, the collective information will be submitted to the FDA. After final approval, MME will be readily available as a treatment option for those specific conditions.